Overview

A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

Status:
RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

lebrikizumab